Drug Shortage Report for TEVA-SPIRONOLACTONE
Report ID | 167212 |
Drug Identification Number | 00613215 |
Brand name | TEVA-SPIRONOLACTONE |
Common or Proper name | SPIRONOLACTONE |
Company Name | TEVA CANADA LIMITED |
Market Status | MARKETED |
Active Ingredient(s) | SPIRONOLACTONE |
Strength(s) | 25MG |
Dosage form(s) | TABLET |
Route of administration | ORAL ORAL |
Packaging size | UD100's |
ATC code | C03DA |
ATC description | POTASSIUM-SPARING AGENTS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2022-08-18 |
Estimated end date | 2023-02-28 |
Actual end date | 2023-04-27 |
Shortage status | Resolved |
Updated date | 2023-04-28 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.